Abstract

The CD6 lymphocyte receptor has been involved in the pathophysiology of different autoimmune disorders and is now considered a feasible target for their treatment. In vitro data show the relevance of CD6 in the stabilization of adhesive contacts between T-cell and antigen-presenting cells, and the modulation of T-cell receptor signals. However, the in vivo consequences of such a function are yet undisclosed due to the lack of suitable genetically modified animal models. Here, the in vitro and in vivo challenge of CD6-deficient (CD6−/−) cells with allogeneic cells was used as an approach to explore the role of CD6 in immune responses under relative physiological stimulatory conditions. Mixed lymphocyte reaction (MLR) assays showed lower proliferative responses of splenocytes from CD6−/− mice together with higher induction of regulatory T cells (Treg, CD4+CD25+FoxP3+) with low suppressive activity on T and B-cell proliferation. In line with these results, CD6−/− mice undergoing a lupus-like disorder induced by chronic graft-versus-host disease (cGvHD) showed higher serum titers of anti-double-stranded DNA and nucleosome autoantibodies. This occurred together with reduced splenomegaly, which was associated with lower in vivo bromodesoxyuridine incorporation of spleen cells and with increased percentages of spleen follicular B cells (B2, CD21+CD23hi) and Treg cells. Interestingly, functional analysis of in vivo-generated CD6−/− Treg cells exhibited defective suppressive activity. In conclusion, the data from MLR and cGvHD-induced lupus-like models in CD6−/− mice illustrate the relevance of CD6 in T (and B) cell proliferative responses and, even more importantly, Treg induction and suppressive function in the in vivo maintenance of peripheral tolerance.

Highlights

  • CD6 was one of the first lymphocyte surface markers identified following the advent of monoclonal antibody technology [1]

  • Available in vitro evidence indicates that adhesive CD6 signaling and/or adhesive CD6–CD166/ALCAM interaction is required for optimal T-cell activation and proliferation [14, 16]

  • Given that the Mixed lymphocyte reaction (MLR) system here used is driven by major histocompatibility complex (MHC) class II allorecognition, purified CD4+ spleen T cells from CD6−/− and CD6+/+ mice were used as responders to irradiated bm12 stimulator cells at 2:1 ratio

Read more

Summary

Introduction

CD6 was one of the first lymphocyte surface markers identified following the advent of monoclonal antibody (mAb) technology [1]. The recent marketing of a humanized anti-CD6 mAb (itolizumab) [3, 4], together with the identification of CD6 gene as a multiple sclerosis susceptibility locus [5, 6], has renewed the interest in the study of this relatively neglected lymphocyte receptor. When translated into more complex in vivo systems, in vitro results have sometimes been misleading. This is a key lesson learned from the sister molecule CD5, since full characterization of its biological role and development of its therapeutic potential could not be realized until CD5-knockout mouse models became available [7]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call